Key Takeaways
- Science Corp., the neurotech firm founded by Neuralink co-founder Max Hodak, is preparing to place its first “biohybrid” neural sensor, a device combining cultured living neurons with electronics, in a human brain, according to an April 14, 2026 TechCrunch report.
- The experimental sensor is a separate program from the company’s commercial PRIMA retinal implant, which received CE marking on July 22, 2026, making it the first brain-computer interface cleared for commercial sale in Europe.
- The biohybrid design targets the field’s core bottleneck, electrode longevity, on the hypothesis that living tissue can integrate with neural tissue where metal electrodes degrade and scar.
- No first-in-human data, clinical indication, timeline, or trial location for the biohybrid sensor has been disclosed; the announcement signals intent, not results.
- Science Corp. raised a $230 million Series C at a $1.5 billion valuation (March 5, 2026) and targets a U.S. PRIMA launch in 2027.
A Company Built on Two Tracks
Science Corp., the neurotechnology company founded by Max Hodak, a co-founder and former president of Neuralink, is preparing to implant its first biohybrid neural sensor in a human being. TechCrunch reported the plan on April 14, 2026, describing a device that pairs cultured living neurons with conventional electronics, an approach that departs sharply from the metal-and-silicon implants that have defined the brain-computer interface (BCI) sector to date.
The disclosure arrives at an unusual moment for the company. Science Corp. is no longer solely a research outfit. Its PRIMA retinal implant, a wireless subretinal photovoltaic device, became the first BCI to receive CE marking, on July 22, 2026, clearing it for sale across roughly 30 European countries. That regulatory milestone gives the company something almost no BCI developer possesses: a revenue-generating product with published clinical evidence behind it.
The biohybrid sensor, by contrast, sits at the opposite end of the maturity spectrum. No indication, patient population, surgical approach, or trial site has been made public. The announcement is best read as a statement of direction rather than a clinical result.
Selling Vision to Fund the Moonshot
The strategic logic behind Science Corp.’s two-track structure is straightforward. PRIMA is a sensory-input device: a 2-millimeter chip placed beneath the retina works with camera-equipped glasses that beam infrared light into the implant, stimulating remaining retinal cells to produce the perception of sight. Its function is narrow, well-defined, and, critically, backed by data.
The evidence base is substantial. NEJM published pivotal trial results on January 14, 2026, alongside an editorial that called PRIMA “the first treatment to restore vision” in advanced geographic atrophy. Thirty-six-month durability data followed on October 5, 2026, and the first patient with Stargardt disease was implanted on October 13, 2026. The technology itself was acquired from Pixium Vision in April 2024, giving Science Corp. a running start on a decade of prior development.
Commercial revenue from PRIMA, in this reading, underwrites the far riskier biohybrid research. The regulatory sequencing, Europe first through the CE mark, with a U.S. launch targeted for 2027 according to STAT, offers a template the company can reuse. The $230 million Series C raised on March 5, 2026, at a $1.5 billion valuation supplies the balance-sheet runway.
The biohybrid bet is a direct answer to the field’s acknowledged durability problem. Metal electrodes implanted in neural tissue tend to degrade and provoke scarring over time, eroding signal quality. The hypothesis being tested is whether living neurons, cultured and integrated into the device, can form a stable biological interface that outlasts inert materials. That is a plausible idea and an unproven one.
Input, Output, and the Full-Duplex Ambition
Most of the competitive field has pursued motor-output BCIs aimed at restoring function for people with paralysis. The numbers illustrate how early the sector still is. Neuralink had implanted roughly 26 participants by June 2026, reporting zero device-related adverse events and demonstrating thought-to-text, robotic-arm control, and thought-to-speech. Synchron has raised $200 million and entered a 2026 pivotal trial. Precision Neuroscience closed a $250 million Series D in September 2026. Paradromics performed its first human implant in June 2025, and China’s Beinao No. 1 is in human trials.
Yet as of mid-2025, the global total of implanted BCI patients numbered fewer than 100. The gap between headline momentum and clinical reality remains wide.
Hodak has argued publicly that “the screen era is ending,” a thesis that positions neural interfaces as the next general-purpose computing platform rather than a narrow medical prosthetic. That vision is converging with a new category: BCI paired with agentic AI. Neuralink has prototyped a Grok agent that a user can summon by thought alone. Such systems raise unresolved questions about consent, data ownership, and who controls decoded neural signals, questions that no regulator has yet answered.
Science Corp.’s biohybrid program, if it works, would push in a different direction: toward a device that is partly biological, blurring the line between implant and tissue.
Expert and Industry Perspectives
Hodak has been candid about PRIMA’s impact. Patients, he said, “go from being almost blind to being able to read every letter on an eye chart and do crossword puzzles” (EL PAÍS, December 2025). The NEJM editorial’s characterization, “the first treatment to restore vision,” gave that claim independent weight.
The biohybrid sensor has no comparable backing. Its characterization rests largely on the April 14 report, which remains the sole detailed public source, and the claim is unverified pending primary confirmation from the company. Cultured human neurons in a commercial device also raise ethical and regulatory questions that current frameworks do not cleanly address: what consent means for tissue with biological origin, whether neural cultures carry any moral status, and what happens if a device must be explanted.
The Bottom Line
The number to watch is signal longevity in months. If a biohybrid sensor can record stably beyond 12 to 24 months, that would mark an inflection point for the entire field. Until primary data are published, the April 2026 announcement should be treated as intent, not result. Watch for trial details, the U.S. PRIMA launch in 2027, and how regulators confront devices built from living neurons. With implanted BCI patients still numbering in the dozens and mainstream adoption likely a decade away, Science Corp.’s wager is that biology, not metal, decides whether neural interfaces last.
